Europe Sodium-dependent Glucose Cotransporter 2 Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Desk Research

Desk research was used to set the clinical and commercial backdrop before the model was built. We leaned on public epidemiology and treatment guidance for diabetes care in Europe, and then aligned it with country-level medicine use patterns and public pricing signals where they are available.

Source types referenced include, for example, the World Health Organization and OECD health statistics, European Commission and national health ministry publications, the European Medicines Agency for approvals and label changes, and peer reviewed journals tracking outcomes and utilization. To understand company-level performance directionally, we also reviewed annual reports, investor decks, and credible press coverage. Where needed, we checked paid subscription sources for company financials and for patent and clinical pipeline context, mainly to validate launch timing and product lifecycle assumptions. These examples are illustrative only and not exhaustive, since many other public sources were also consulted for data collection, validation, and clarification.

Primary Interviews and Surveys

Primary work focused on validating what desk research cannot fully pin down, especially the on-ground mix across countries and how demand is shifting between diabetes and cardio-renal use. We spoke with prescribers, pharmacy channel stakeholders, and industry participants across major European markets, and then used their inputs to confirm adoption pace, pricing behavior, and near-term policy impacts.

Distribution of primary research fieldwork respondents

Sizing starts from a top-down build where the treated type 2 diabetes pool is reconstructed by country, then filtered through SGLT2 class penetration and average therapy cost to reach a value estimate. After that picture is formed, we test it using selective bottom-up checks such as sampled country sales roll-ups, channel feedback on unit volumes, and price per pack signals, which we use to adjust outliers.

Key inputs used in the model include diagnosed type 2 diabetes prevalence and treated share, new initiation rates for SGLT2 therapy, switching patterns from other oral classes, average daily dose and persistence assumptions, and net price progression after tenders or reimbursement updates. We track label expansions and guideline adoption as well, since they change the eligible patient pool and therefore the demand curve.

For forecasting, scenario analysis was used so adoption and pricing can be flexed in a simple but realistic way. Assumptions for each country were aligned to the consensus view collected from interviews, and then cross-checked against recent policy and prescribing signals. Where a bottom-up check could not be built cleanly for a smaller country, we used peer country analogs and then revalidated the resulting shares with experts.

Validation is handled through several passes, where we compare the model outputs against independent signals like diabetes drug spend direction, therapy mix trends, and country-level reimbursement movements. If a country output deviates sharply from expected uptake or pricing behavior, we re-check the input chain and, when needed, reconnect with primary sources to understand what changed.

Before sign-off, the model and narrative go through multi-step internal reviews so the calculation logic, assumptions, and country splits are consistent. The report is refreshed annually, and interim updates are made when major events occur such as a label change, pricing shock, or a meaningful shift in guidelines. Right before delivery, a final analyst pass is completed so clients receive the most current view available.

Published market sizes for Europe SGLT2 inhibitors can differ even when the topic name looks similar, since each publisher may count different drugs, years, and pricing concepts. Differences also come from how countries are grouped, whether volume is converted using list price or estimated net price, and how quickly assumptions are refreshed when reimbursement and tender outcomes change.

The main gap comes from whether fixed-dose combinations and expanded cardio-renal use are counted inside the SGLT2 total. Mordor Intelligence treats the market as SGLT2 inhibitor drug revenues, and it keeps country pricing aligned to net, not list, by updating discount assumptions when new policy signals appear.

Benchmark comparison

Across the three figures, the spread is mostly explained by what is counted as SGLT2 revenue and by how price is translated into a comparable USD value across countries and years. When the model is tied back to treated patients, adoption rates, and country price behavior, it is easier to reproduce and simpler to update without breaking the logic chain.